Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Post-Mkt 03-03 17:36:05 EST

27.85

-0.25

-0.89%

盘后28.24

+0.39+1.40%

17:35 EST

High28.24	Low26.94	Vol6.18M
Open27.33	D1 Closing28.10	Amplitude4.62%
Mkt Cap19.93B	Tradable Cap13.01B	Total Shares715.70M
T/O170.89M	T/O Rate1.32%	Tradable Shares467.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":27.85,"timestamp":1772571600000,"preClose":28.1,"halted":0,"volume":6178101,"hourTrading":{"tag":"盘后","latestPrice":28.24,"preClose":27.85,"latestTime":"17:35 EST","volume":1097815,"amount":30646572.80118,"timestamp":1772577336882,"change":0.39,"changeRate":0.014004,"amplitude":0.072531},"delay":0,"changeRate":-0.00889679715302491,"floatShares":467000000,"shares":715701137,"eps":-1.173433,"marketStatus":"Post-Mkt","change":-0.25,"latestTime":"03-03 17:36:05 EST","open":27.33,"high":28.24,"low":26.942,"amount":170888485.420158,"amplitude":0.046192,"askPrice":28.68,"askSize":50,"bidPrice":27,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-1.173433,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772586000000},"marketStatusCode":4,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":28.1,"preHourTrading":{"tag":"盘前","latestPrice":27.57,"preClose":28.1,"latestTime":"09:28 EST","volume":2365,"amount":65546.85005,"timestamp":1772548082264,"change":-0.53,"changeRate":-0.018861,"amplitude":0.023488},"postHourTrading":{"tag":"盘后","latestPrice":28.24,"preClose":27.85,"latestTime":"17:35 EST","volume":1097815,"amount":30646572.80118,"timestamp":1772577336882,"change":0.39,"changeRate":0.014004,"amplitude":0.072531},"volumeRatio":1.403622,"impliedVol":0.381,"impliedVolPercentile":0.6255},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2616775113","title":"Roivant Sciences Raises Buyback Program to $1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2616775113","media":"Dow Jones","labels":["shareholding"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2616775113?lang=en_us&edition=fundamental","pubTime":"2026-03-04 06:11","pubTimestamp":1772575860,"startTime":"0","endTime":"0","summary":"Roivant Sciences has added $500 million to its current share repurchase program.The pharmaceutical company said Tuesday that its board of directors approved a share repurchase program of up to $1 billion, including a previously announced $500 million authorization.The repurchase program will be funded with available cash and cash equivalents on hand and doesn't have an expiration date, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roivant Sciences Raises Buyback Program to $1 Billion","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2616374941","title":"Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374941","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374941?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:23","pubTimestamp":1772572996,"startTime":"0","endTime":"0","summary":"Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent disputeMarch 3  - Moderna MRNA.O has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences ROIV.O, and Arbutus Biopharma ABUS.O up to $2.25 billion to settle a long-running legal fight over the technology that made its COVID-19 vaccine possible, the companies said on Tuesday.Under the deal, Moderna will pay $950 million upfront in July 2026, with an additional $1.3 billion that depends on the outcome of a separate legal appeal.  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4N3ZR21P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","ABUS","BK4007","BK4551","BK4568","BK4139","BK4585","ROIV","MRNA","MRNY","BK4501","BK4533","BK4588","MRNX","BK4548","BK4532"],"gpt_icon":0},{"id":"2616374698","title":"BRIEF-Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374698","media":"Reuters","labels":["corporation","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374698?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:20","pubTimestamp":1772572836,"startTime":"0","endTime":"0","summary":"BRIEF-Genevant Sciences And Arbutus Biopharma Announce $2.25 Billion Global Settlement With ModernaMarch 3 (Reuters) - Arbutus Biopharma Corp ABUS.O:GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA7RZBMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ABUS","ROIV","BK4139"],"gpt_icon":0},{"id":"2616437439","title":"Roivant Sciences - Arbutus Is Currently Evaluating a Return of Capital to Shareholders for Q3 of Calendar Year 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616437439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616437439?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:15","pubTimestamp":1772572500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA7RZBMP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABUS","ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2616374668","title":"Roivant Sciences: Under Settlement, Genevant to Give Moderna Non-Exclusive License to Lnp Delivery Technology for Infectious Disease Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374668?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:15","pubTimestamp":1772572500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUAH61QL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRNY","BK4568","MRNA","BK4532","BK4139","BK4533","ABUS","BK4585","BK4551","BK4588","ROIV","BK4501","MRNX","BK4534","BK4007","BK4548"],"gpt_icon":0},{"id":"2616374397","title":"Roivant Sciences : Board Approved $1 Bln Share Repurchase Program, Inclusive of $500 Mln Authorization That Was Approved in June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2616374397","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616374397?lang=en_us&edition=fundamental","pubTime":"2026-03-04 05:15","pubTimestamp":1772572500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUAH61QL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV","ABUS"],"gpt_icon":0},{"id":"2616342826","title":"Priovant wins FDA Priority Review for brepocitinib dermatomyositis NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342826","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342826?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539253,"startTime":"0","endTime":"0","summary":"Priovant Therapeutics, an affiliate of Roivant Sciences Ltd., said the FDA has accepted its new drug application for brepocitinib to treat dermatomyositis and granted Priority Review. The FDA set a PDUFA target action date in the third quarter of 2026, and Priovant expects a U.S. launch at the end of September 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL1npYzn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014039.USD","SG9999014013.SGD","BK4112","ROIV","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4007","LU2210150020.SGD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","BK4588","NDAQ"],"gpt_icon":0},{"id":"2616344439","title":"Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344439?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA2DS9Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ROIV","BK4139","BK4007"],"gpt_icon":0},{"id":"2616342877","title":"Roivant Sciences Ltd - FDA Assigns Pdufa Date Q3 2026, Launch Expected September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342877?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA2DS9Z6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2613752990","title":"Roivant Sciences President and Vant Chair Frank Torti Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2613752990","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613752990?lang=en_us&edition=fundamental","pubTime":"2026-02-24 09:40","pubTimestamp":1771897249,"startTime":"0","endTime":"0","summary":"Frank Torti, President and Vant Chair of Roivant Sciences Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL5Db3wk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences President and Vant Chair Frank Torti Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2612427295","title":"Roivant President and Immunovant CEO Eric Venker Disposes of Roivant Sciences Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612427295","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612427295?lang=en_us&edition=fundamental","pubTime":"2026-02-19 06:57","pubTimestamp":1771455468,"startTime":"0","endTime":"0","summary":"Eric Venker, President & Immunovant CEO, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL8Yrs1h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","ROIV","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"2611197863","title":"Roivant Sciences Director Keith S. Manchester Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611197863","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611197863?lang=en_us&edition=fundamental","pubTime":"2026-02-14 10:02","pubTimestamp":1771034574,"startTime":"0","endTime":"0","summary":"Keith S. Manchester, Director, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260214:nNDL4xnGNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2611192267","title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611192267","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611192267?lang=en_us&edition=fundamental","pubTime":"2026-02-14 09:46","pubTimestamp":1771033596,"startTime":"0","endTime":"0","summary":"QVT Financial LP has reported a disposal of common shares of Roivant Sciences Ltd. The transaction involved the sale of 425,000 shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260214:nNDL3nBvNG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2610673249","title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2610673249","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610673249?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:54","pubTimestamp":1770850442,"startTime":"0","endTime":"0","summary":"Mayukh Sukhatme, President & Chief Investment Officer of Roivant Sciences Ltd., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbz53gH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences President & CIO Mayukh Sukhatme Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"2610047641","title":"Roivant Sciences price target raised to $35 from $26 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2610047641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610047641?lang=en_us&edition=fundamental","pubTime":"2026-02-10 19:36","pubTimestamp":1770723403,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Roivant Sciences (ROIV) to $35 from $26 and keeps a Buy rating on the shares. The firm views the company’s P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-35-from-26-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-35-from-26-at-citi-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ROIV","BK4139"],"gpt_icon":0},{"id":"2610043659","title":"Roivant Sciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2610043659","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610043659?lang=en_us&edition=fundamental","pubTime":"2026-02-09 22:56","pubTimestamp":1770648960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2026 09:56 ET (14:56 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2610508545","title":"Roivant Sciences price target raised to $26 from $22 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2610508545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610508545?lang=en_us&edition=fundamental","pubTime":"2026-02-09 04:45","pubTimestamp":1770583514,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $26 from $22 and keeps a Neutral rating on the shares post the f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-26-from-22-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-26-from-22-at-bofa-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2610778075","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunovant (IMVT) and Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610778075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610778075?lang=en_us&edition=fundamental","pubTime":"2026-02-09 01:20","pubTimestamp":1770571217,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunovant (IMVT – Research Report) and Roivant Sciences (ROIV – ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunovant-imvt-and-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-immunovant-imvt-and-roivant-sciences-roiv-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","ROIV","LU0029874061.USD","HCSG","BK4139","LU0128526141.USD","BK4588","BK4581","LABU","BK4585","BK4007","IMVT","BK4137","XLV"],"gpt_icon":0},{"id":"2609578298","title":"Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Bullish Profitability Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2609578298","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609578298?lang=en_us&edition=fundamental","pubTime":"2026-02-08 11:11","pubTimestamp":1770520284,"startTime":"0","endTime":"0","summary":"Roivant Sciences (ROIV) just posted its Q3 2026 numbers with total revenue of about US$2.0 million and a basic EPS loss of US$0.38, alongside a net income loss, excluding extra items, of US$265.9 million. The company has seen quarterly revenue move from US$9.0 million in Q3 2025 to US$2.0 million in Q3 2026, while basic EPS shifted from a loss of US$0.22 to a loss of US$0.38 over the same period. This sets the scene for investors to weigh near term revenue scale against the size of ongoing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-q3-loss-of-us2659-million-tests-bullis","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ROIV","BK4007","BK4112"],"gpt_icon":0},{"id":"2609454901","title":"Roivant Sciences (ROIV) Is Up 19.4% After Advancing Phase 2 Pipeline Despite Wider Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2609454901","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609454901?lang=en_us&edition=fundamental","pubTime":"2026-02-07 10:16","pubTimestamp":1770430573,"startTime":"0","endTime":"0","summary":"Roivant Sciences reported third-quarter 2025 results showing sales of US$2.00 million and a net loss of US$265.89 million, while subsidiaries Priovant and Pulmovant advanced key Phase 2 programs in rare inflammatory and pulmonary diseases.\nTogether with positive Phase 2 brepocitinib data in cutaneous sarcoidosis and rapid enrollment of mosliciguat’s PHocus trial, Roivant’s pipeline activity is increasingly central to its story despite widened losses.\nWe’ll now examine how Roivant’s progress...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-194-after-advancing-phase-2-pipe","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-roiv-is-up-194-after-advancing-phase-2-pipe","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.2997},{"period":"3month","weight":0.398},{"period":"6month","weight":1.2319},{"period":"1year","weight":1.6164},{"period":"ytd","weight":0.2949}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.085297},{"month":4,"riseRate":0.8,"avgChangeRate":0.019894},{"month":5,"riseRate":0.4,"avgChangeRate":0.032328},{"month":6,"riseRate":0.8,"avgChangeRate":0.015077},{"month":7,"riseRate":0.8,"avgChangeRate":0.040575},{"month":8,"riseRate":0.6,"avgChangeRate":0.00833},{"month":9,"riseRate":0.4,"avgChangeRate":0.013102},{"month":10,"riseRate":0.6,"avgChangeRate":0.101456},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}